Melanotan use linked to first reported case of Pyoderma Gangrenosum in a 65-year-old woman
Background
Pyoderma Gangrenosum (PG) is a rare, severe neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Its exact cause remains elusive, but nearly half of cases are associated with underlying systemic inflammatory conditions such as rheumatological disorders, hematological malignancies, or inflammatory bowel disease. While drug-induced PG is an infrequent occurrence, the specific association with Melanotan has never been documented, highlighting a critical gap in understanding potential adverse effects of this peptide.
Study Design
This case report details a 65-year-old woman who self-administered Melanotan and subsequently developed ulcerated wounds. Clinically, four distinct wounds with erythematous edges were observed on her abdomen, precisely corresponding to the peptide injection sites. The diagnosis of Pyoderma Gangrenosum was established based on the characteristic appearance and rapid progression of the wounds, their unresponsiveness to multiple courses of antibiotics, and negative bacteriology results, including tests for Panton-Valentine leukocidin Staphylococcus aureus. Treatment commenced with topical betamethasone, steroid occlusion tape, and systemic prednisolone, followed by topical Dermovate as prednisolone was tapered.
Results
The patient presented with four ulcerated wounds on her abdomen, directly at the sites of Melanotan injection. These lesions exhibited classic features of Pyoderma Gangrenosum, including rapid enlargement and erythematous borders. Crucially, the wounds showed no improvement despite multiple courses of antibiotics, and comprehensive bacteriological cultures, including for Panton-Valentine leukocidin Staphylococcus aureus, returned negative, ruling out common infectious causes. This lack of response to antibiotics, combined with the clinical presentation, strongly supported the PG diagnosis. Treatment initiated with topical betamethasone and systemic prednisolone yielded a good therapeutic effect. Prednisolone was gradually titrated down, and topical Dermovate was introduced. > After several months of consistent treatment, the wounds completely healed, leaving behind characteristic cribriform scars, confirming the resolution of the dermatosis. This case represents the first instance of Melanotan-induced Pyoderma Gangrenosum ever reported in medical literature.
Key Findings
- A 65-year-old woman developed four ulcerated wounds at Melanotan injection sites.
- Wounds were diagnosed as Pyoderma Gangrenosum due to appearance, progression, and unresponsiveness to antibiotics.
- Treatment with topical betamethasone and systemic prednisolone led to good effect.
- Wounds healed with classic cribriform scars after several months of treatment.
- This is the first reported case of Melanotan-induced Pyoderma Gangrenosum.
Why It Matters
This case report significantly expands the known spectrum of potential adverse drug reactions associated with Melanotan use, particularly highlighting a severe dermatological complication like Pyoderma Gangrenosum. Individuals considering or using Melanotan should be acutely aware of this rare but serious risk, especially given the peptide's unregulated availability and self-administration practices. This finding underscores the critical need for caution and medical oversight when using such compounds. While it doesn't directly alter a specific peptide protocol, it adds a crucial safety consideration, emphasizing that any new or worsening skin lesions, particularly at injection sites, warrant immediate medical evaluation to rule out conditions like PG, which require specific immunosuppressive treatment.
